HY-0007

N/A

Report date: 2025/12/19 10:20:01

Base Information

Drug NameHY-0007
Drug Alias NameHY-0007
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAnti-PD-1Anti-T cell immunoglobulin and ITIM domainsAnti-IL15
TargetsProgrammed cell death protein 1T cell immunoglobulin and ITIM domainsInterleukin-15
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEuropeMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSichuan Huiyu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSichuan Huiyu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A